Search
Influenza A virus A/Victoria/2454/2019 IVR-207 (H1N1) antigen (propiolactone inactivated)
go.drugbank.com/drugs/DB15711ApprovedWithdrawnVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen
Influenza B virus B/Victoria/705/2018 BVR-11 antigen (propiolactone inactivated)
go.drugbank.com/drugs/DB15713ApprovedWithdrawnVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen
Influenza A virus A/Hong Kong/2671/2019 NIB-121 (H3N2) antigen (UV, formaldehyde inactivated)
go.drugbank.com/drugs/DB15715ApprovedWithdrawnVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen
Influenza B virus B/Washington/02/2019 antigen (UV, formaldehyde inactivated)
go.drugbank.com/drugs/DB15716ApprovedWithdrawnVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen
Influenza A virus A/Hawaii/66/2019 (H1N1) live (attenuated) antigen
go.drugbank.com/drugs/DB15756ApprovedVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen
Influenza B virus B/Washington/02/2019 live (attenuated) antigen
go.drugbank.com/drugs/DB15758ApprovedVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen
Influenza A virus A/Tasmania/503/2020 IVR-221 (H3N2) antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB16705ApprovedVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen
Influenza A virus A/Cambodia/e0826360/2020 IVR-224 (H3N2) antigen (propiolactone inactivated)
go.drugbank.com/drugs/DB16723ApprovedWithdrawnVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen
Influenza A virus A/Cambodia/e0826360/2020 IVR-224 (H3N2) antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB16725ApprovedWithdrawnVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen
Protamine sulfate
go.drugbank.com/drugs/DB09141ApprovedInvestigationalDespite the relative importance of protamine sulfate's medical indication, the medication can notoriously cause a variety of potentially rare but genuinely severe adverse effects that include systemic
Products: Protamine Sulfate Inj 10mg/ml USP, Prosulf 10mg/ml Solution for Injection